Mid-Cap
Here Is What You Should Know About Joby Aviation’s Offering
Joby Aviation Seeks $202 Million in Funding to Advance Certification and Manufacturing of Electric Air Taxis Joby Aviation (JOBY), a...
Apogee Therapeutics’ APG777 Demonstrates Promising Longevity in Phase 1 Study, Ahead of Key 2025 Milestones
Nine-Month Follow-Up Data Validates APG777's Extended Half-Life and Safety, as Investors Look to Pipeline Updates and Upcoming Clinical Data In...
Intuitive Surgical Q3 2024 Earnings: Robust Growth Amid Market Challenges
Key Factors to Watch as da Vinci V Expansion Continues Intuitive Surgical (ISRG) has reported strong third-quarter financial results for...
Study Highlights the Life-Saving Potential of Obesity Drugs and Strengthens the Bullish Case for Viking Therapeutics
VKTX’s Innovative Drug Candidates Could Unlock Significant Value for Patients and Investors A recent study has shone new light on...
180 Life Sciences Corp. Enters the iGaming Industry with Blockchain-Enabled Platform
Leveraging blockchain and cryptocurrency technology, 180 Life Sciences aims to revolutionize the online casino market In a strategic move that...
Larimar Therapeutics: Targeting the Root Cause of Friedreich’s Ataxia with Nomlabofusp
Biotech company poised to lead FA treatment with innovative protein replacement therapy Larimar Therapeutics (LRMR) has emerged as a promising...
SoFi Strikes $2 Billion Deal with Fortress Investment to Expand Personal Loan Business
Strategic Partnership Marks a Major Step in Diversifying Revenue Sources SoFi Technologies (SOFI), an online bank with a vision of...
Affirm Holdings Upgraded to Neutral as Lower Interest Rates Brighten Outlook
Reduced Funding Costs and GMV Growth to Bolster the Buy Now, Pay Later Pioneer Shares of Affirm Holdings (AFRM), a...
CATX Showcases Breakthroughs in Radiopharmaceutical Development at Oppenheimer Summit
Targeted radiopharmaceuticals promising multiple catalysts and clinical advancements heading into 2024 CATX (CATX), a company pioneering targeted radiopharmaceutical therapies, provided...
OnKure Positioned for Success with PI3Kα Inhibitor OKI-219 in Breast Cancer
Targeting H1047R Mutations for Improved Efficacy and Reduced Toxicity in an Expanding Market OnKure Therapeutics (OKUR) is making waves in...
